Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis

Related Experiment Videos

L Dekker1, W Armbrust, C M A Rademaker

  • 1Department of Pediatric Rheumatology and Immunology, University Medical Center Utrecht, Het Wilhelmina Kinder Ziekenhuis, Utrecht, The Netherlands.

Clinical and Experimental Rheumatology
|April 16, 2004
PubMed

Insights

Anti-tumor necrosis factor alpha (TNFalpha) agents like etanercept effectively treat severe juvenile idiopathic arthritis (JIA). Physicians must monitor for adverse events during prolonged use of these important biologic therapies.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Severe juvenile idiopathic arthritis (JIA) often requires advanced treatment strategies.
  • Anti-tumor necrosis factor alpha (TNFalpha) agents are established therapies for various autoimmune conditions.
  • Etanercept is approved for polyarticular JIA unresponsive to methotrexate (MTX).

Purpose of the Study:

  • To review the adverse events associated with anti-TNFalpha agents in JIA treatment.
  • To provide physicians with an overview of potential side effects for informed patient management.

Main Methods:

  • Literature review of reported adverse events.
  • Analysis of clinical trial data and post-marketing surveillance for etanercept and infliximab in JIA.

Main Results:

  • Anti-TNFalpha agents demonstrate efficacy in controlling JIA inflammation and preventing joint destruction.
  • Both etanercept and infliximab show significant clinical benefits in pediatric patients.
  • Potential side effects require vigilant monitoring, particularly with long-term administration.

Conclusions:

  • Anti-TNFalpha therapies are valuable for managing severe JIA.
  • Awareness of adverse events is crucial for optimizing safety and efficacy in pediatric rheumatology.
  • Continued surveillance is necessary to fully characterize the long-term safety profile.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: